Skip to content

Botulinum Toxin Injections for Men with Erectile Dysfunction

Intracavernosal Botulinum Toxin Use in the Treatment of Erectile Dysfunction

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
REBEC
Registry ID
RBR-5kkspwk
Enrollment
Unknown
Registered
2025-10-23
Start date
2024-03-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile dysfunction due to organic cause

Interventions

This is a prospective, randomized, controlled, two-arm, double-blind clinical trial. A total of 60 participants who meet the eligibility criteria will be randomly assigned to one of the intervention g
E02.319.267.530

Sponsors

Hospital Universitário Pedro Ernesto
Lead Sponsor
Hospital Universitário Pedro Ernesto
Collaborator

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Having an International Index of Erectile Function – 5 items (IIEF-5) score of 21 points or less; being over 18 years of age; currently using at least one available treatment option for erectile dysfunction, which must be continued throughout the study; having normal libido; and having a partner able to engage in sexual intercourse for treatment assessment.

Exclusion criteria

Exclusion criteria: Presence of urogenital neoplasms; history of radical prostatectomy; testosterone levels below 350 ng/ml; diagnosed depression with the use of antidepressants; anatomical abnormalities of the genital tract; insufficient sexual activity to allow assessment of the response to the proposed treatment; and any clinical condition that contraindicates the treatment planned in the study.

Design outcomes

Primary

MeasureTime frame
Change in the score of the International Index of Erectile Function – 5 items (IIEF-5), comparing the values obtained before the intervention, at three months, and at six months after the application, with the aim of evaluating the efficacy of intracavernosal botulinum toxin compared to placebo in the treatment of erectile dysfunction.

Secondary

MeasureTime frame
Monitoring the occurrence of local and systemic adverse events related to the intervention, recorded throughout the entire follow-up period, to assess the safety of intracavernosal botulinum toxin administration compared to placebo.

Countries

Brazil

Contacts

Public ContactGabriel Crelier

Hospital Universitário Pedro Ernesto

gabriel_crelier@hotmail.com+55(21)981995943

Outcome results

None listed

Source: REBEC (via WHO ICTRP)